Endothelin-converting enzyme activity in human cerebral circulation. 2002

Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
Department of Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt, Germany. hvatter@arcor.de

OBJECTIVE An increased level of endothelin (ET)-1 seems to be involved in the development of augmented cerebrovascular resistance in different pathological conditions, most notably vasospasm after subarachnoid hemorrhage. Therefore, interfering with the ET synthesis or ET receptor blockade may be a promising approach in the treatment of cerebral vasospasm after subarachnoid hemorrhage. Although the receptors mediating the effects of ET-1 human cerebrovasculature are well characterized, data concerning the functionally relevant ET-converting enzyme (ECE) activity are scarce. METHODS ECE activity was determined in organ bath studies by the use of intraoperatively harvested human pial arteries. The level of ECE activity was analyzed by comparing the shift in the concentration effect curves obtained for ET-1 and its precursor, big ET-1. In addition, the presence of ECE-1alpha immunoreactivity was studied in human cerebral tissue. RESULTS ECE-1alpha immunoreactivity was found, although not consistently, in human cerebral arteries and was restricted to the endothelium. In isolated pial arterial segments, ET-1 and big ET-1 induced concentration-related contractions with mean pD(2) values of 9.25 +/- 0.34 and 7.13 +/- 0.17, respectively, yielding a 123-fold shift of big ET-1 versus mature ET-1. Preincubation with phosphoramidon (10(-4) mol/L) resulted in a small yet significant inhibition of the contraction induced by big ET-1. CONCLUSIONS The results of our study indicate the presence of functional ECE activity and ECE-1alpha immunoreactivity in human cerebral arteries. Furthermore, the data suggest the presence of ECE-like activity that differs from that of ECE-1alpha.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007432 Intraoperative Period The period during a surgical operation. Intraoperative Periods,Period, Intraoperative,Periods, Intraoperative
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008297 Male Males
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010841 Pia Mater The innermost layer of the three meninges covering the brain and spinal cord. It is the fine vascular membrane that lies under the ARACHNOID and the DURA MATER. Mater, Pia,Maters, Pia,Pia Maters
D011498 Protein Precursors Precursors, Protein
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain

Related Publications

Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
April 1993, FEBS letters,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
December 1997, British journal of pharmacology,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
August 1994, Atherosclerosis,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
October 1993, Fiziologicheskii zhurnal imeni I.M. Sechenova,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
January 2002, Methods in molecular biology (Clifton, N.J.),
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
January 1998, Journal of cardiovascular pharmacology,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
November 1991, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
January 1998, Journal of immunoassay,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
January 1989, British journal of clinical pharmacology,
Hartmut Vatter, and Kay Mursch, and Michael Zimmermann, and Petra Zilliken, and Herbert Kolenda, and Volker Seifert, and Lothar Schilling
November 1997, The American journal of physiology,
Copied contents to your clipboard!